admin

July 23, 2019 Among adults who started antiretroviral therapy, levels of HIV drug resistance before treatment with two non-nucleoside reverse transcriptase inhibitors, or NNRTIs, exceeded 10% in 12 of the 18 countries that reported data to the WHO between 2014 and 2018, […]

BIOMEDICINE AND HEALTH: Public Health. The WHO recommends an integrase inhibitor to fight HIV. Dolutegravir is a new, more potent, affordable HIV drug with a lower likelihood of generating resistance and is better tolerated compared to other available antiretrovirals. Studies have shown the benefits of using it in

Published 24/07/2019 17:39:23CET MEXICO CITY, July 24 (From EUROPA PRESS Special Correspondent, David Guirao) Dr. Josep Maria Gatell, one of the world's leading experts on HIV and senior global medical director of the pharmaceutical company ViiV Healthcare, says that, "throughout 2020," Dr. Gatell, HIV expert: "In

Islatravir plus doravirine may offer a new dual therapy option Liz Highleyman July 25, 2019 Image from Jean-Michel Molina's live stream at NIC 2019. Islatravir, the first nucleoside reverse transcriptase translocation inhibitor, plus the recently approved non-nucleoside reverse transcriptase inhibitor doravirine (Pifeltro) may

Trial vaccine could protect against HIV for more than five years. Gus Cairns, July 25, 2019. Daniel Stieh, presenting the ASCENT study, at NIC 2019. Photo by Liz Highleyman. New results from a Phase IIa study of the vaccine, APPROACH, announced today at the Society Conference.

Four days later, three days off for HIV treatment, as effective as continuous treatment. Keith Alcorn, July 25, 2019. Ronald Landman at IAS 2019. Photo by Liz Highleyman. Taking HIV medication four days a week was as effective as daily treatment for people who

Gus Cairns, July 25, 2019. Kathleen Ryan of Monash University. Photo by Gus Cairns. Several studies presented at the 10th International AIDS Society Conference on HIV Science (NIC 2019) in Mexico City analyzed who discontinued HIV pre-exposure prophylaxis (PrEP) after starting it as part of a treatment plan.

July 25, 2019 | ALEXANDRA WARD One strategy to increase the use of pre-exposure prophylaxis (PrEP) in areas where its implementation is limited is to promote same-day initiation. In Latin America, where the HIV epidemic persists, especially among men who have sex with men (MSM) and women

Liz Highleyman July 24, 2019 Jean-Michel Molina at IAS 2019. Photo by Liz Highleyman. The World Health Organization (WHO) has updated its pre-exposure prophylaxis (PrEP) recommendation to include event-driven PrEP taken before and after sex, also called on-demand PrEP or the 2-in-1 program.

Gus Cairns, July 24, 2019. Islatravir is the latest HIV drug name to be added to the growing list of antiretrovirals. The drug, formerly known as MK-8591, was the subject of one of the most anticipated studies presented at the 10th International AIDS Society Conference on Science.